Skip to main content
OpenTrials
Completed

NCT Number: NCT05328986

Kidney Disease After COVID-19

To understand the long-term epidemiology, develop effective risk-prediction and stratification tools, and understand the pathobiology of kidney disease in COVID-19 survivors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Acute Kidney Injury Chronic Kidney Injury Coronaviridae Infections Coronavirus Infections Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Kidney Diseases Lung Diseases Male Urogenital Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Respiratory Tract Diseases Respiratory Tract Infections Urogenital Diseases Urologic Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale School of Medicine, New Haven, Connecticut, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Criteria:

Inclusion criteria

  • Adults, age ≥18 years
  • Confirmed diagnosis of COVID-19

Exclusion criteria

  • No confirmed diagnosis of COVID-19

Treatment and study plan

Primary outcomes

  1. estimated Glomerular Filtration Rate (eGFR)

    Time frame: yearly for 4 years after COVID exposure

    Kidneys filter blood by removing waste and extra water to make urine. The kidney's filtration rate, called the glomerular filtration rate (GFR), shows how well the kidneys are filtering. A normal GFR is 60 or higher.

Secondary outcomes

  1. Urine Albumin-to-Creatinine Ratio (UACR)

    Time frame: yearly for 4 years after COVID exposure

    Albuminuria is present when UACR is greater than 30 mg/g and is a marker for chronic kidney disease. Albuminuria is used to diagnose and monitor kidney disease.

  2. Urine protein/creatinine ratio (UPCR)

    Time frame: yearly for 4 years after COVID exposure

    Urine protein/creatinine ratio - Protein creatinine ratio in the urine quantifies the loss of the protein and helps in further evaluation of the kidney function. Normal ratio: < 0.20

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • Johns Hopkins University
  • New Jersey Medical School
  • University of Michigan
  • Yale New Haven Health System Center for Healthcare Solutions

Registry information

Official study title

Multi-center Assessment of Survivors for Kidney Disease After COVID-19

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Apr 14, 2022
Registry last updated
Jul 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.